Rating #4
Stanley Freeman Druckenmiller
Duquesne Family Office
Portfolio value
Stocks
Performance
1 Year
+40.10%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Stanley Freeman Druckenmiller’s Portfolio: Q1 2026
Top10 stocks: 55.61% of the portfolio
Stanley Freeman Druckenmiller’s Trades: Q1 2026
Adds
New Buys
Sold Outs
Cuts
5.34ppt
3.94ppt
2.23ppt
G
Share Count Chg. (%)
Add +100.00%
1.07ppt
0.68ppt
0.72ppt
0.72ppt
0.31ppt
0.59ppt
0.02ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1  NTRA | Add +21.99% | $215.20 | $118.84M | 5.34ppt | |
2  YPF | Add +433.12% | $37.85 | $99.51M | 3.94ppt | |
3  STM | Add +237.78% | $31.29 | $57.55M | 2.23ppt | |
Add +100.00% | $92.01 | $35.64M | 1.07ppt | ||
5  TWLO | Add +100.00% | $123.00 | $22.36M | 0.68ppt | |
Add +100.00% | $220.17 | $22.02M | 0.72ppt | ||
7  SNDK | Add +100.00% | $564.88 | $21.55M | 0.72ppt | |
8  ADMA | Add +512.85% | $15.78 | $20.41M | 0.31ppt | |
9  STX | Add +100.00% | $381.56 | $19.35M | 0.59ppt | |
10  SE | Add +16.50% | $107.18 | $16.70M | 0.02ppt |
Stanley Freeman Druckenmiller’s Holdings: Q1 2026
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
1 NTRA | Medical Laboratories | $117.36 | Add +21.99% | 3.06M | $612.69M | 18.14% 5.34ppt | 2.24% | 15 Quarters | Q1 2026 | |
2  INSM | Pharmaceutical Pres | $88.13 | Cut -22.11% | 1.15M | $188.72M | 5.59% -0.15ppt | 0.54% | 8 Quarters | Q1 2026 | |
3  TSM | Semiconductors | $181.79 | Cut -8.80% | 495.28K | $167.38M | 4.96% 1.28ppt | 0.01% | 7 Quarters | Q1 2026 | |
- | $31.77 | 0.00% | 4.23M | $162.31M | 4.81% 1.82ppt | - | 2 Quarters | Q4 2025 | ||
- | $191.92 | New Buy +100.00% | 821.00K | $157.57M | 4.67% 4.67ppt | - | 1 Quarter | Q1 2026 | ||
6 YPF | Petroleum Refining | $44.34 | Add +433.12% | 3.24M | $149.57M | 4.43% 3.94ppt | 0.83% | 8 Quarters | Q1 2026 | |
7 I EWZ | - | $31.77 | Cut -3.28% | 3.44M | $131.92M | 3.91% 1.40ppt | 1.71% | 4 Quarters | Q1 2026 | |
8  TBBB | Retail-Grocery Stores | $31.31 | Add +16.23% | 3.11M | $109.97M | 3.26% 1.27ppt | 2.70% | 4 Quarters | Q1 2026 | |
9  AA | - | $54.18 | Add +8.53% | 1.49M | $99.06M | 2.93% 1.31ppt | 0.57% | 2 Quarters | Q1 2026 | |
10  NAMS | Pharmaceutical Pres | $28.37 | 0.00% | 3.07M | $98.28M | 2.91% 0.51ppt | 2.68% | 7 Quarters | Q4 2025 | |
11 SE | Misc. Business Services | $129.30 | Add +16.50% | 1.10M | $91.08M | 2.70% 0.02ppt | 0.18% | 4 Quarters | Q1 2026 | |
12 STM | Semiconductors | $32.00 | Add +237.78% | 2.61M | $90.28M | 2.67% 2.23ppt | 0.26% | 2 Quarters | Q1 2026 | |
13  WWD | Industrial Apparatus | $150.85 | Cut -64.23% | 211.36K | $75.65M | 2.24% -1.73ppt | 0.35% | 10 Quarters | Q1 2026 | |
14  TEVA | Pharmaceutical Pres | $18.91 | Cut -59.53% | 2.38M | $71.60M | 2.12% -1.96ppt | 0.21% | 7 Quarters | Q1 2026 | |
15  ROKU | Cable & Pay TV Services | $83.31 | Add +28.68% | 750.19K | $70.98M | 2.10% 0.69ppt | 0.51% | 5 Quarters | Q1 2026 | |
16  AVGO | Semiconductors | $309.51 | New Buy +100.00% | 195.96K | $60.65M | 1.80% 1.80ppt | 0.00% | 1 Quarter | Q1 2026 | |
17 S SPY Call | - | $617.85 | 0.00% | 90.00K | $58.53M | 1.73% 0.37ppt | - | 4 Quarters | Q2 2025 | |
18  CPNG | Retail-Catalog & Mail-Order | $30.64 | Cut -60.62% | 2.67M | $50.36M | 1.49% -2.06ppt | 0.15% | 21 Quarters | Q1 2026 | |
19  OPCH | Home Health Care | $31.00 | Add +7.02% | 1.87M | $50.30M | 1.49% 0.25ppt | 1.18% | 4 Quarters | Q1 2026 | |
20  AMZN Call | Retail-Catalog & Mail-Order | $219.55 | Add +100.00% | 200.00K | $41.65M | 1.23% 0.72ppt | - | 2 Quarters | Q1 2026 |
NEWSLETTER
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersOur content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.